{
    "name": "fidaxomicin",
    "comment": "Rx",
    "other_names": [
        "Dificid"
    ],
    "classes": [
        "Macrolides"
    ],
    "source": "https://reference.medscape.com/drug/dificid-fidaxomicin-999663",
    "pregnancy": {
        "common": [
            "Limited available data in pregnant women are insufficient to inform any drug-associated risk for major birth defects; miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Embryo-fetal reproduction studies in rats and rabbits dosed intravenously during organogenesis revealed no evidence of harm to fetus at exposures 65-fold or higher than the clinical exposure at the recommended dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information on presence of fidaxomicin or its main metabolite, OP-1118, in human milk, the effects on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Only use for infection proven or strongly suspected to be caused by C difficile to avoid development of drug resistant bacteria; therapy not effective for treatment of other types of infections due to minimal systemic absorption of fidaxomicin",
                "Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face reported; discontinue and treat appropriately if reaction occurs therapy should be instituted",
                "Some patients with hypersensitivity reactions also reported a history of allergy to other antimicrobials#macrolides",
                "Use in the absence of proven or strongly suspected ",
                "C difficile",
                " infection is unlikely to provide benefit to the patient and increases risk of developing drug-resistant bacteria"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Not dependent on CYP450 enzymes for metabolism",
                        "Fidaxomicin and its main metabolite, OP-1118, are P-gp substrates, but not significantly affected by P-gp inhibitors",
                        "Based on results of studies coadministered with cyclosporine, fidaxomicin may be co-administered with P-gp inhibitors and no dose adjustment is recommended"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal distension",
            "percent": null
        },
        {
            "name": "abdominal tenderness",
            "percent": null
        },
        {
            "name": "dyspepsia",
            "percent": null
        },
        {
            "name": "dysphagia",
            "percent": null
        },
        {
            "name": "flatulence",
            "percent": null
        },
        {
            "name": "intestinal obstruction",
            "percent": null
        },
        {
            "name": "megacolon",
            "percent": null
        },
        {
            "name": "Investigations",
            "percent": null
        },
        {
            "name": "Increased blood alkaline phosphatase",
            "percent": null
        },
        {
            "name": "decreased blood bicarbonate",
            "percent": null
        },
        {
            "name": "increased hepatic enzymes",
            "percent": null
        },
        {
            "name": "decreased platelet count",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hyperglycemia",
            "percent": null
        },
        {
            "name": "metabolic acidosis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Drug eruption",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        }
    ]
}